Oxaliplatina Hikma

Oxaliplatin, the active ingredient in Oxaliplatina Hikma, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous use. It is employed in the treatment of colorectal cancer and other gastrointestinal malignancies, typically in adult patients. GNH USA supplies Oxaliplatina Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH USA supplies Oxaliplatina Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Oxaliplatin is a platinum‑based chemotherapeutic that interferes with DNA replication in rapidly dividing cancer cells.

- Colorectal cancer: improves survival when used in combination regimens for metastatic or adjuvant therapy. - Gastric cancer: contributes to tumor response as part of combination chemotherapy. - Pancreatic cancer: used in selected protocols to enhance disease control. - Ovarian cancer: may be incorporated into multi‑drug regimens for refractory disease. - Esophageal cancer: added to standard regimens to increase response rates. - Small‑cell lung cancer: occasionally used off‑label within clinical trials.

Oxaliplatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset during or after infusion. - Peripheral neuropathy: tingling or numbness in hands and feet, often dose‑related. - Diarrhea: watery stools that may require supportive care. - Fatigue: generalized tiredness during treatment cycles. - Myelosuppression: reduced blood cell counts, increasing infection risk. - Elevated liver enzymes: transient changes in hepatic function tests.

Serious or Rare Side Effects: - Severe hypersensitivity reactions: anaphylaxis or bronchospasm during infusion. - Acute hemolytic anemia: rapid destruction of red blood cells. - Severe neutropenia with fever: risk of life‑threatening infection. - Cardiotoxicity: arrhythmias or myocardial ischemia in rare cases. - Renal impairment: acute kidney injury requiring monitoring. - Thrombotic microangiopathy: rare clotting disorder affecting small vessels.

Oxaliplatin requires careful monitoring and patient counseling before and during therapy.

- Renal function: assess baseline creatinine and adjust if impairment is present. - Hepatic function: evaluate liver enzymes and bilirubin prior to dosing. - Neuropathy risk: monitor for early signs of peripheral neuropathy and adjust dose as needed. - Hematologic status: perform complete blood counts before each cycle to detect myelosuppression. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or infant risks. - Storage: Store below 25°C: keep in the original packaging, protect from light and moisture.

Oxaliplatin can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid): - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): increase risk of kidney damage. - Highly protein‑bound drugs (e.g., warfarin): may displace oxaliplatin and alter plasma levels.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron): may be required to control infusion‑related nausea. - Antioxidants (e.g., vitamin C, E): theoretical reduction of platinum‑induced cytotoxicity. - CYP450 inducers/inhibitors: limited data, monitor for unexpected toxicity. - Radiotherapy: concurrent use may enhance neurotoxicity. - Blood transfusions: can affect laboratory monitoring of blood counts.